Showing 20 of 206 recruiting trials for “t-cell-prolymphocytic-leukemia”
Zanubrutinib and Venetoclax in CLL (ZANU-VEN)
Clinical Study of Hospital-manufactured CD19 CAR-T in Children and Adolescents With Acute Lymphoblastic Leukemia
Pneumococcal Pneumonia Vaccine Series (PCV20 and PPSV23) in Patients With Chronic Lymphocytic Leukemia Associated Immunodeficiency, PROTECT CLL Trial
👨⚕️ Daniel Ermann, MD, Huntsman Cancer Institute/ University of Utah📍 1 site📅 Started Jan 2022View details ↗
A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies
CAP-100 for Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia
RecruitingNCT05014165 ↗
Backtracking Leukemia-Typical Somatic Mutations in Cord Blood
👨⚕️ Adam de Smith, PhD, University of Southern California Keck School of Medicine📍 1 site📅 Started Aug 2021View details ↗
A Personalized Neoantigen Cancer Vaccine in Treatment Naïve, Asymptomatic Patients With IGHV Unmutated CLL.
Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.
Anti-CD19, Dual Co-stimulatory (4-1BB, CD3ζ) Chimeric Antigen Receptor T-cells in Patients With Relapsed/Refractory Aggressive Lymphoma or Acute Lymphoblastic Leukemia (ALL)
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
Study to Test OBI-3424 in Patients With T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LBL)
Blinatumomab After TCR Alpha Beta/CD19 Depleted HCT
Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia
👨⚕️ Jianxiang Wang, Dr., Institute of Hematology & Blood Diseases Hospital, China📍 11 sites📅 Started Dec 2020View details ↗
Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
👨⚕️ Natalie Grover, MD, UNC Lineberger Comprehensive Cancer Center📍 1 site📅 Started Nov 2020View details ↗
A Study of Murine CD19 CAR-T Therapy for Patients With Relapsed or Refractory CD19+ B-cell Hematological Malignancies
Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma
Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
RecruitingNCT04290000 ↗
Collection of Biological Samples From Patients Treated With CAR-T Cells for Hematological Malignancies
Study of APG-2575 as a Single Agent or in Combination With Other Therapeutic Agents for CLL/SLL
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →